Treatment strategies for juvenile idiopathic arthritis

被引：21

作者：

Klein, Ariane ^{[1
]}

Horneff, Gerd ^{[1
]}

机构：

[1] Asklepios Clin Sankt Augustin, Dept Pediat, D-53757 St Augustin, Germany

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 18期

关键词：

abatacept; adalimumab; anakinra; canakinumab; etanercept; infliximab; juvenile idiopathic arthritis; leflunomide; methotrexate; tocilizumab; USSR DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; T-CELLS; METHOTREXATE; ETANERCEPT; EFFICACY; CHILDREN; PLACEBO; SAFETY; THERAPY;

D O I：

10.1517/14656560903386300

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Importance of the field: Treatment of juvenile idiopathic arthritis has markedly improved in the last decade and induction of remission became a reachable goal. Areas covered in this review: For this review the current literature about clinical trials in JIA is summarized including those substances and strategies currently not approved for treatment. What the reader will gain: With this information, the reader receives an overview on the current available treatment options and will be enabled to guide modern treatment of the several JIA subgroups. Take home messages: Current treatment strategies in juvenile idiopathic arthritis (JIA) - including conventional and new therapeutics, biologics - have changed the outcome of JIA. Treatment with TNF inhibitors lead to a rapid and sustained suppression of inflammation and can effectively be used for treatment of polyarticular JIA. Blockers to further pro-inflammatory cytokines, IL-1 and IL-6 are most valuable for treatment of systemic-onset JIA. Blockers of T-cell activation are an alternative approach, slowly acting but targeting to complete inactivation of the disease. Future concepts for the post-biologics era of treatment of rheumatic diseases use antigen-specific tolerance induction and modulation of the immune response. Clinical remission has now become a reachable target in the treatment of JIA.

引用

页码：3049 / 3060

页数：12

共 57 条

[1]

ANSELL BM, 1991, CLIN EXP RHEUMATOL, V9, P201

[2] Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis [J].

Armbrust, W ;

Kamphuis, SSM ;

Wolfs, TWF ;

Fiselier, TJW ;

Nikkels, PG ;

Kuis, W ;

Wulffraat, NM .

RHEUMATOLOGY, 2004, 43 (04) :527-529

[3] PHARMACOKINETICS OF SUBCUTANEOUS METHOTREXATE [J].

BALIS, FM ;

MIRRO, J ;

REAMAN, GH ;

EVANS, WE ;

MCCULLY, C ;

DOHERTY, KM ;

MURPHY, RF ;

JEFFRIES, S ;

POPLACK, DG .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1882-1886

[4]

Beukelman T, 2008, CLIN EXP RHEUMATOL, V26, P700

[5]

BEUKELMAN T, 2007, ARTHRITIS RHEUM S, V54, pS136

[6] PENICILLAMINE AND HYDROXYCHLOROQUINE IN THE TREATMENT OF SEVERE JUVENILE RHEUMATOID-ARTHRITIS - RESULTS OF THE USA USSR DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL [J].

BREWER, EJ ;

GIANNINI, EH ;

KUZMINA, N ;

ALEKSEEV, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (20) :1269-1276

[7] A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies [J].

Burgos-Vargas, R ;

Vázquez-Mellado, J ;

Pacheco-Tena, C ;

Hernández-Garduño, A ;

Goycochea-Robles, MV .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) :941-942

[8] Vaccination with selected synovial T cells in rheumatoid arthritis [J].

Chen, Guangjie ;

Li, Ningli ;

Zang, Ying C. Q. ;

Zhang, Dongqing ;

He, Dongyi ;

Feng, Guozhang ;

Ni, Liqing ;

Xu, Rong ;

Wang, Li ;

Shen, Baihua ;

Zhang, Jingwu Z. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (02) :453-463

[9]

Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202

[10] METHOTREXATE IN RESISTANT JUVENILE RHEUMATOID-ARTHRITIS - RESULTS OF THE USA-USSR DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

GIANNINI, EH ;

BREWER, EJ ;

KUZMINA, N ;

SHAIKOV, A ;

MAXIMOV, A ;

VORONTSOV, I ;

FINK, CW ;

NEWMAN, AJ ;

CASSIDY, JT ;

ZEMEL, LS .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (16) :1043-1049

← 1 2 3 4 5 6 →